NCT06630390View on ClinicalTrials.gov

Daridorexant to Prevent Delirium After Heart Surgery

PHASE2CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

November 11, 2024

Primary Completion Date

February 16, 2025

Study Completion Date

February 16, 2025

Conditions
POSTOPERATIVE DELIRIUMPOSTOPERATIVE COGNITIVE DECLINE
Interventions
DRUG

Daridorexant 50 mg

Administered consistent with labeling from the US Food and Drug Administration.

OTHER

Placebo

Identical appearing to daridorexant

Trial Locations (1)

14642

University of Rochester Medical Center, Rochester

All Listed Sponsors
lead

University of Rochester

OTHER

NCT06630390 - Daridorexant to Prevent Delirium After Heart Surgery | Biotech Hunter | Biotech Hunter